
Covid 19 vaccines in cancer patients (pts), real world data (RWD) from 1069 Belong.life users ePoster ID

#1594P

globally widespread

Eli Sapir*, Noy Moisa, Alon Litvin, Eliran Malki, Daniel Vorobiof**, Assuta Ashdod Hospital, Belong life, New York, USA, Belong Tail, Tel-Aviv, Israel

*No COI to declare, **Correspondence: dvorobiof@gmail.com



968/1069 pts (90.55%) received vaccination and 4 (0.41%) developed a Covid 19 infection, while 101/1069 pts (9.45%) were not vaccinated and 9 (8.9%) developed Covid 19 infection. Analysing the whole cohort, the RR of being infected by Covid 19 amongst the non-vaccinated cancer pts is 21.5 larger (95% CI 6.76 to 68.77) than those vaccinated patients (p<0.0001)

diagnoses were Breast Cancer (35.2%), gynecological (14.4%), gastrointestinal (13.3%), lung cancers (9.7%) and 59% of the pts had chemotherapy, 14.2% immunotherapy, 32.8% had radiotherapy during the 12 months vaccination. mRNA vaccines were

82.3% of the pts had none (39.3%) or mild (43%) side-effects and only 2.4% reported severe side effects, which lasted 1-3 days (89.4%) mainly of sore arm (42.5%), headache (23.3%), fatigue

In 96% there was no delay or stoppage of their therapy and management. 968/1069 pts (90.55%) received the vaccination and 4 (0.41%) developed a Covid 19 infection, while 101/1069 pts (9.45%) were not vaccinated and 9 (8.9%) developed the viral infection.

The relative risk (RR) of being infected by Covid19 amongst the nonvaccinated cancer pts is 21.5 larger (95% CI 6.76 to 68.77) than the vaccinated patients (p<0.0001).